trifluoperazine has been researched along with Metabolic Syndrome in 1 studies
Metabolic Syndrome: A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components of metabolic syndrome include ABDOMINAL OBESITY; atherogenic DYSLIPIDEMIA; HYPERTENSION; HYPERGLYCEMIA; INSULIN RESISTANCE; a proinflammatory state; and a prothrombotic (THROMBOSIS) state.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In the first-generation antipsychotic (FGA) group, the highest prevalence of metabolic syndrome was among patients treated with trifluoperazine and flupenthixol decanoate (66." | 3.79 | Metabolic syndrome and antipsychotic monotherapy treatment among schizophrenia patients in Malaysia. ( Ananjit, S; Badiah, Y; Bulgiba, A; Habil, MH; Hairi, NN; Haslina, MY; Hatim, A; Mahmud, B; Ramli, MA; Said, MA; Sapini, Y; Shah, M; Zafidah, W, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Said, MA | 1 |
| Hatim, A | 1 |
| Habil, MH | 1 |
| Zafidah, W | 1 |
| Haslina, MY | 1 |
| Badiah, Y | 1 |
| Ramli, MA | 1 |
| Ananjit, S | 1 |
| Sapini, Y | 1 |
| Shah, M | 1 |
| Mahmud, B | 1 |
| Bulgiba, A | 1 |
| Hairi, NN | 1 |
1 other study available for trifluoperazine and Metabolic Syndrome
| Article | Year |
|---|---|
Metabolic syndrome and antipsychotic monotherapy treatment among schizophrenia patients in Malaysia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Cross-Sectional Studies; Female; Flupenthixol; | 2013 |